Active Uptake of Ulifloxacin from Plasma to Lung That Controls Its Concentration in Epithelial Lining Fluid
スポンサーリンク
概要
- 論文の詳細を見る
Ulifloxacin is a new quinolone antibiotic and it is effective against pneumonia. We previously showed that it is highly distributed into the epithelial lining fluid (ELF) in rats, which might be resulting from certain active transport. The transport system has not been, however, clarified yet. In this study, we attempted to characterize the distribution mechanism of ulifloxacin into the rat ELF. We also aimed to elucidate the feature of ulifloxacin uptake in rat lung and human lung adenocarcinoma cells (Calu-3). In infusion studies, ulifloxacin concentrations in the ELF and lung were higher than that in the plasma, and decreased by co-administration of sparfloxacin or azithromycin to the level of plasma concentration. Integration plot analysis showed that active uptake of ulifloxacin from the plasma to lung was also inhibited by sparfloxacin and azithromycin. In in vitro studies, time and temperature-dependent uptake into Calu-3 was observed, and this uptake was inhibited by sparfloxacin and azithromycin as observed in the rat lung. Additionally sparfloxacin inhibited the active uptake of ulifloxacin into Calu-3 more strongly than levofloxacin as observed in the rat lung. These results suggest that active uptake of ulifloxacin from the plasma to lung controls the distribution of ulifloxacin from the plasma to ELF, and that the uptake of ulifloxacin into Calu-3 has partly similar characteristics to its uptake into the rat lung. We believe our study will contribute to much better understanding of antibiotic efficacy against pathogens which cause pneumonia.
- 日本薬学会の論文
著者
-
AOKI Makoto
Applied Pharmacology Research Laboratories, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.
-
IGUCHI Maki
Applied Pharmacology Research Laboratories, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.
-
HAYASHI Hiroyuki
Applied Pharmacology Research Laboratories, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.
-
SHIBASAKI Shigeki
Applied Pharmacology Research Laboratories, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.
-
KUROSAWA Tohru
Applied Pharmacology Research Laboratories, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.
-
HAYASHI Masahiro
School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
-
Hayashi Masahiro
School Of Pharmacy Tokyo University Of Pharmacy And Life Science
-
Shibasaki Shigeki
Applied Pharmacology Research Laboratories, Pharmaceutical Research Center, Meiji Seika Kaisha Ltd.
-
Hayashi Hiroyuki
Applied Pharmacology Research Laboratories, Pharmaceutical Research Center, Meiji Seika Kaisha Ltd.
-
Iguchi Maki
Applied Pharmacology Research Laboratories, Pharmaceutical Research Center, Meiji Seika Kaisha Ltd.
-
Kurosawa Tohru
Applied Pharmacology Research Laboratories, Pharmaceutical Research Center, Meiji Seika Kaisha Ltd.
-
Aoki Makoto
Applied Pharmacology Research Laboratories, Pharmaceutical Research Center, Meiji Seika Kaisha Ltd.
関連論文
- Proposal of Membrane Transport Mechanism of Protein-Unbound Ulifloxacin into Epithelial Lining Fluid Determined by Improved Microdialysis(Biopharmacy)
- Prulifloxacin (PUFX) の肝臓への取り込み機構の解明
- Bile Acid-Induced Elevated Oxidative Stress in the Absence of Farnesoid X Receptor(Biochemistry)
- Active Uptake of Ulifloxacin from Plasma to Lung That Controls Its Concentration in Epithelial Lining Fluid
- Comparative Analysis of In Vitro and In Vivo Pharmacokinetic Parameters Related to Individual Variability of GTS-21 in Canine
- 耳鼻科領域感染症及び肺炎の小児患者における新規経口カルバペネム剤テビペネム・ピボキシルの母集団薬物動態解析
- The Effects of Emulsifying Agents on Disposition of Lipid-Soluble Drugs Included in Fat Emulsion